Prospective Audit of the Introduction of Insulin Glargine (Lantus) Into Clinical Practice in Type 1 Diabetic Patients
- Ian W. Gallen, MD, FRCP and
- Celia Carter, RGN
- From the South Buckinghamshire National Health Services Trust, Wycombe Hospital, Buckinghamshire, U.K.
- Address correspondence to Dr. Ian Gallen, Diabetes Centre, Wycombe Hospital, High Wycombe, Buckinghamshire HP11 2TT, U.K. E-mail: ian.gallen{at}sbucks.nhs.uk
Insulin glargine is a modified basal insulin analog that has been recently introduced, and following guidance from the National Institute for Clinical Excellence (NICE), it is now widely available in the U.K. (1). Studies in type 1 diabetes demonstrate that compared with NPH insulin, fasting blood glucose and hypoglycemic episodes are reduced and patient satisfaction is improved (2–7). To confirm whether these reported benefits are also achieved in routine clinical practice, we conducted a prospective audit of patients attending our diabetes clinic practice transferring to insulin glargine.
There were …
